Astec LifeSciences Limited (NSE:ASTEC)
India · Delayed Price · Currency is INR 885.45
+5.95 (0.68%)
Aug 4, 2025, 2:21 PM IST
Aerovate Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 3,999 | 3,781 | 4,577 | 6,282 | 6,766 | 5,549 | Upgrade |
Other Revenue | 31.57 | 31.57 | 9.41 | 3.31 | 3.34 | 37.96 | Upgrade |
Revenue | 4,030 | 3,813 | 4,586 | 6,285 | 6,769 | 5,587 | Upgrade |
Revenue Growth (YoY) | 4.63% | -16.86% | -27.03% | -7.15% | 21.16% | 5.68% | Upgrade |
Cost of Revenue | 2,879 | 3,056 | 3,249 | 4,069 | 3,920 | 3,457 | Upgrade |
Gross Profit | 1,151 | 757.2 | 1,338 | 2,216 | 2,849 | 2,130 | Upgrade |
Selling, General & Admin | 611.22 | 621.68 | 629 | 533.27 | 513.32 | 394 | Upgrade |
Other Operating Expenses | 849.53 | 797.59 | 762.03 | 911.8 | 788.77 | 582.09 | Upgrade |
Operating Expenses | 1,920 | 1,856 | 1,754 | 1,782 | 1,646 | 1,233 | Upgrade |
Operating Income | -768.81 | -1,099 | -415.94 | 434.56 | 1,203 | 897.14 | Upgrade |
Interest Expense | -402.77 | -362.76 | -248.56 | -201.58 | -86.95 | -42.71 | Upgrade |
Interest & Investment Income | 8.03 | 8.03 | 1.51 | 40.49 | 2.63 | 7.85 | Upgrade |
Currency Exchange Gain (Loss) | 15.9 | 15.9 | 49.71 | 83.92 | 72.45 | 30.4 | Upgrade |
Other Non Operating Income (Expenses) | -2.43 | 1.74 | -3.09 | -3.85 | -0.35 | -4.76 | Upgrade |
EBT Excluding Unusual Items | -1,150 | -1,436 | -616.37 | 353.54 | 1,191 | 887.92 | Upgrade |
Gain (Loss) on Sale of Assets | 20.18 | 20.18 | -1.11 | -5.24 | 0.14 | 2.34 | Upgrade |
Pretax Income | -1,124 | -1,410 | -617.48 | 349.47 | 1,211 | 890.71 | Upgrade |
Income Tax Expense | 156.56 | -62.78 | -148.57 | 93.53 | 312.43 | 240.02 | Upgrade |
Earnings From Continuing Operations | -1,280 | -1,347 | -468.91 | 255.94 | 898.83 | 650.69 | Upgrade |
Minority Interest in Earnings | -0.42 | -0.41 | -0.39 | -0.29 | -0.24 | -0.2 | Upgrade |
Net Income | -1,281 | -1,348 | -469.3 | 255.65 | 898.59 | 650.49 | Upgrade |
Net Income to Common | -1,281 | -1,348 | -469.3 | 255.65 | 898.59 | 650.49 | Upgrade |
Net Income Growth | - | - | - | -71.55% | 38.14% | 36.91% | Upgrade |
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | 20 | Upgrade |
Shares Change (YoY) | -0.00% | 0.01% | 0.02% | 0.04% | 0.05% | 0.09% | Upgrade |
EPS (Basic) | -65.31 | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 | Upgrade |
EPS (Diluted) | -65.31 | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 | Upgrade |
EPS Growth | - | - | - | -71.56% | 38.06% | 36.84% | Upgrade |
Free Cash Flow | - | -302.21 | -1,253 | -426.03 | -803.74 | -1,107 | Upgrade |
Free Cash Flow Per Share | - | -15.41 | -63.88 | -21.73 | -41.01 | -56.50 | Upgrade |
Dividend Per Share | - | - | 1.500 | 1.500 | 1.500 | 1.500 | Upgrade |
Gross Margin | 28.57% | 19.86% | 29.17% | 35.26% | 42.09% | 38.12% | Upgrade |
Operating Margin | -19.08% | -28.83% | -9.07% | 6.91% | 17.78% | 16.06% | Upgrade |
Profit Margin | -31.78% | -35.34% | -10.23% | 4.07% | 13.28% | 11.64% | Upgrade |
Free Cash Flow Margin | - | -7.93% | -27.32% | -6.78% | -11.87% | -19.81% | Upgrade |
EBITDA | -320.99 | -670.07 | -61.53 | 759.35 | 1,536 | 1,146 | Upgrade |
EBITDA Margin | -7.96% | -17.57% | -1.34% | 12.08% | 22.70% | 20.51% | Upgrade |
D&A For EBITDA | 447.82 | 429.14 | 354.41 | 324.79 | 332.88 | 248.47 | Upgrade |
EBIT | -768.81 | -1,099 | -415.94 | 434.56 | 1,203 | 897.14 | Upgrade |
EBIT Margin | -19.08% | -28.83% | -9.07% | 6.91% | 17.78% | 16.06% | Upgrade |
Effective Tax Rate | - | - | - | 26.76% | 25.79% | 26.95% | Upgrade |
Revenue as Reported | 4,082 | 3,869 | 4,638 | 6,412 | 6,870 | 5,628 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.